| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
22.04
|
|
2
|
Screening for epidermal growth factor receptor mutations in lung cancer.
|
N Engl J Med
|
2009
|
13.47
|
|
3
|
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
|
Nat Genet
|
2012
|
5.64
|
|
4
|
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
|
J Clin Oncol
|
2007
|
3.88
|
|
5
|
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
3.43
|
|
6
|
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
|
Nature
|
2011
|
3.18
|
|
7
|
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
|
Clin Cancer Res
|
2011
|
3.15
|
|
8
|
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
|
Clin Cancer Res
|
2004
|
2.54
|
|
9
|
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
|
Oncogene
|
2003
|
1.88
|
|
10
|
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
|
PLoS One
|
2007
|
1.86
|
|
11
|
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
|
J Thorac Oncol
|
2010
|
1.85
|
|
12
|
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
|
Lung Cancer
|
2005
|
1.71
|
|
13
|
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung.
|
Clin Cancer Res
|
2008
|
1.62
|
|
14
|
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
|
Cancer Lett
|
2003
|
1.60
|
|
15
|
Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer.
|
Clin Lung Cancer
|
2009
|
1.60
|
|
16
|
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
|
Clin Cancer Res
|
2014
|
1.59
|
|
17
|
A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
1.47
|
|
18
|
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
|
Clin Cancer Res
|
2008
|
1.43
|
|
19
|
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
|
PLoS One
|
2008
|
1.43
|
|
20
|
DNA repair and cisplatin resistance in non-small-cell lung cancer.
|
Lung Cancer
|
2002
|
1.42
|
|
21
|
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
|
PLoS One
|
2009
|
1.36
|
|
22
|
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
|
Clin Cancer Res
|
2004
|
1.32
|
|
23
|
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
|
J Thorac Oncol
|
2008
|
1.30
|
|
24
|
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
|
J Natl Cancer Inst
|
2011
|
1.27
|
|
25
|
Guideline on the requirements of external quality assessment programs in molecular pathology.
|
Virchows Arch
|
2012
|
1.24
|
|
26
|
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
|
Clin Lung Cancer
|
2009
|
1.17
|
|
27
|
mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
|
J Natl Cancer Inst
|
2011
|
1.14
|
|
28
|
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
|
J Clin Oncol
|
2005
|
1.14
|
|
29
|
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.
|
Mol Cancer Ther
|
2009
|
1.12
|
|
30
|
Predicting the outcome of chemotherapy for lung cancer.
|
Curr Opin Pharmacol
|
2006
|
1.10
|
|
31
|
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
|
Clin Cancer Res
|
2003
|
1.08
|
|
32
|
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
|
J Transl Med
|
2010
|
1.02
|
|
33
|
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
|
Curr Opin Oncol
|
2010
|
1.02
|
|
34
|
Genetic testing for chemotherapy in non-small cell lung cancer.
|
Lung Cancer
|
2003
|
1.00
|
|
35
|
Influence of genetic markers on survival in non-small cell lung cancer.
|
Drugs Today (Barc)
|
2003
|
0.98
|
|
36
|
Platinum resistance related to a functional NER pathway.
|
J Thorac Oncol
|
2007
|
0.95
|
|
37
|
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
|
Clin Cancer Res
|
2006
|
0.95
|
|
38
|
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.
|
Future Oncol
|
2007
|
0.95
|
|
39
|
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.
|
Pharmacogenomics
|
2002
|
0.92
|
|
40
|
The role of Wnt signaling in cancer and stem cells.
|
Future Oncol
|
2005
|
0.91
|
|
41
|
Applications of genomics in NSCLC.
|
Lung Cancer
|
2005
|
0.90
|
|
42
|
BRCA1: a new genomic marker for non-small-cell lung cancer.
|
Clin Lung Cancer
|
2008
|
0.89
|
|
43
|
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
|
Lung Cancer
|
2010
|
0.89
|
|
44
|
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
|
Semin Oncol
|
2003
|
0.88
|
|
45
|
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
|
Oncotarget
|
2013
|
0.88
|
|
46
|
Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
|
Clin Lung Cancer
|
2013
|
0.86
|
|
47
|
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
|
PLoS One
|
2010
|
0.85
|
|
48
|
Molecular predictors of response to chemotherapy in lung cancer.
|
Semin Oncol
|
2004
|
0.84
|
|
49
|
Role of genotyping in non-small cell lung cancer treatment: current status.
|
Drugs
|
2011
|
0.84
|
|
50
|
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
|
Clin Lung Cancer
|
2004
|
0.83
|
|
51
|
Biomarkers in lung oncology.
|
Pulm Pharmacol Ther
|
2010
|
0.82
|
|
52
|
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.
|
J Transl Med
|
2011
|
0.82
|
|
53
|
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
|
Cancer Invest
|
2008
|
0.82
|
|
54
|
Treatment and detection of ALK-rearranged NSCLC.
|
Lung Cancer
|
2013
|
0.82
|
|
55
|
Predictive biomarkers in the management of EGFR mutant lung cancer.
|
Ann N Y Acad Sci
|
2010
|
0.81
|
|
56
|
A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes.
|
DNA Repair (Amst)
|
2011
|
0.81
|
|
57
|
Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
|
Anticancer Res
|
2007
|
0.81
|
|
58
|
Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.
|
Drug News Perspect
|
2010
|
0.81
|
|
59
|
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
|
Curr Opin Oncol
|
2006
|
0.80
|
|
60
|
Translational oncogenomics: toward rational therapeutic decision-making.
|
Curr Opin Oncol
|
2002
|
0.80
|
|
61
|
The promise of pharmacogenomics: gemcitabine and pemetrexed.
|
Oncology (Williston Park)
|
2004
|
0.79
|
|
62
|
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors.
|
Future Oncol
|
2009
|
0.79
|
|
63
|
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.
|
PLoS One
|
2012
|
0.79
|
|
64
|
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
|
Clin Lung Cancer
|
2005
|
0.79
|
|
65
|
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
|
Lung Cancer
|
2009
|
0.78
|
|
66
|
Pemetrexed in previously treated non-small-cell lung cancer.
|
Oncology (Williston Park)
|
2004
|
0.78
|
|
67
|
Methylation patterns and chemosensitivity in NSCLC.
|
Adv Exp Med Biol
|
2006
|
0.77
|
|
68
|
Future directions in the second-line treatment of non-small cell lung cancer.
|
Semin Oncol
|
2006
|
0.77
|
|
69
|
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
|
Cancer Chemother Pharmacol
|
2008
|
0.77
|
|
70
|
Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
|
Lung Cancer
|
2013
|
0.77
|
|
71
|
Translational research in glioblastoma multiforme: molecular criteria for patient selection.
|
Future Oncol
|
2008
|
0.77
|
|
72
|
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
|
Invest New Drugs
|
2004
|
0.76
|
|
73
|
Predicting response to chemotherapy with early-stage lung cancer.
|
Cancer J
|
2011
|
0.76
|
|
74
|
Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
|
Drug Metabol Personal Ther
|
2016
|
0.76
|
|
75
|
c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer.
|
Transl Oncogenomics
|
2006
|
0.76
|
|
76
|
Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
|
J Natl Cancer Inst
|
2002
|
0.75
|
|
77
|
Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
|
Clin Lung Cancer
|
2008
|
0.75
|
|
78
|
Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP).
|
Lung Cancer
|
2010
|
0.75
|
|
79
|
Determinants of response and resistance to cytotoxics.
|
Semin Oncol
|
2002
|
0.75
|